MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 9, 2025

Primary Completion Date

April 6, 2026

Study Completion Date

April 6, 2026

Conditions

HIV Infection

Interventions

DRUG

MK-4646

MK-4646 in capsular form administered orally

Trial Locations (2)

RECRUITING

"PMSI Republican Clinical Hospital T.Mosneaga ( Site 0002)", Chisinau

RECRUITING

ARENSIA Exploratory Medicine ( Site 0001), Bucharest

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY